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INTRODUCTION                                                    
Transurethral resection of a superficial 
bladder tumor (TURT) is used to remove 
the tumor for histological diagnosis of tumor 
cell type, grade and stage1. About 70% of 
these tumors recur as superficial tumors, 
but some progress. Stage T1, high grade, 
multiplicity and carcinoma in situ are risk 
factors and increase the possibility of tumor 
progression2,3. To minimize tumor recurrence, 
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observed in cases with stage T1, or grade-3 tumors or in cases associated with carcinoma in situ.
Conclusion: TURT with adjuvant intravesical BCG therapy is considered the first treatment 
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adjuvant intravesical  immunotherapy or 
chemotherapy is usually used after TURT. 
Several studies have confirmed the efficacy 
of Bacillus Calmette Guerin (BCG) in 
reducing tumor recurrence and delaying its 
progression4. In the European Association of 
Urology (EAU) guidelines for the treatment 
of bladder cancer BCG is considered more 
effective than intravesical chemotherapy and 
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the abdomen and pelvis was indicated in 13 
patients with impaired renal function.
Hematuria was the most common clinical 
presentation as shown in Table 1. Mean serum 
creatinine was 1.1 ± 0.2 (range: 0.4 to 1.5) 
mg/dL in 147 and 2.6 ± 0.5 (range: 1.9 to 4.9) 
mg/dL in the remaining 13 patients.
All patients underwent complete TURT in 
a single session (113 cases) or in two sessions 
(47 patients). To assess the tumor stage and 
grade all resected tumor tissue, as well as a 
biopsy from the tumor base, random mucosal 
biopsies from the remaining bladder and a 
biopsy specimen of the prostatic urethra were 
sent for histopathologic analysis. Repeated 
TURT was indicated in 26 patients due to the 
absence of muscle tissue in the first specimen. 
Staged resection of multiple or large-volume 
tumors was done 2 weeks after the first 
session in 21 patients. The histopathologic 
features of the tumor cell type, stage, grade, 
multiplicity and association of carcinoma in 
situ were documented in all cases.
All low-risk patients with stage-Ta, grade-1 
TCC who received no adjuvant therapy were 
excluded from this study, while cases of Ta 
with a higher tumor grade (2-3) or cases with 
T1, grade-1 TCC were considered high or 
intermediate-risk patients and were included 
in the study.
is advocated as the first treatment option in 
high-risk patients and in the intermediate-
risk patients after failure of intravesical 
chemotherapy1. 
Intravesical BCG instillation protocols 
with various doses of BCG, intervals of 
instillation and periods of BCG maintenance 
have been used. The objective of this study 
is to report on the Al-Azhar experience with 
special emphasis on the failure rate and 
factors  affecting  the  results  of  intravesical 
BCG instillation after complete transurethral 
resection of   superficial   transitional   cell 
carcinoma (TCC) of the urinary bladder.
PATIENTS AND METHODS                                  
This prospective study conducted between 
2002  and  2008  included 160  patients  (113 
men  and  47  women) with superficial TCC 
of the bladder treated by  TURT  followed 
by  intravesical  BCG instillation. The mean 
follow-up was 37 ± 4 (range 3 to 64) months. 
The mean age of the patients was 62.2 ± 9.5 
(range: 27 to 83) years. Informed consent was 
routinely taken from all patients.
All patients were evaluated by clinical 
assessment, routine laboratory tests, 
abdomino-pelvic ultrasound and excretory 
urography. Pelvic CT scan was performed in 
109 patients, while non-contrast CT scan of 






















Fig. 1:  Overall survival at a mean follow-up of 3 years












Fig. 2: Survival according to age groups (<50 and > 50 years)
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Two weeks after TURT, a  6-week 
induction course of intravesical BCG 
instillations was started. It consisted of 
a weekly administration of 80 mg BCG 
dissolved in 50 ml of normal saline instilled 
through a urethral catheter into an empty 
bladder and held for at least 2 hours. This 
BCG induction course was followed after 2 
weeks by clinical assessment, urine cytology 
(34 cases) and pelvic ultrasound to determine 
the presence of any bladder tumor. 
If no recurrence was present, a maintenan-
ce course of monthly 80 mg BCG was given 
in the first year, then every 3 months for the 
next 2 years. In patients with recurrence of 
superficial TCC after the induction course of 
BCG, a second session of TURT and BCG 
instillation was performed 
Failure of BCG was considered in cases 
with tumor progression or recurrence after 
the second BCG course. These cases were 
managed by either repeated TURT with intra-
vesical chemotherapy or salvage cystectomy. 
For post-operative assessment, clinical 
evaluation and pelvic ultrasound were done 
for all patients before the induction course of 
BCG and every 3 months during the main-
tenance course. Urine cytology was done in 
34 patients with high-grade TCC and in cases 
with associated carcinoma in situ. Abdomino-
pelvic CT scan was done in cases with tumor 
recurrence or tumor progression. Furthermo-
re, evaluation of the upper urinary tract was 
performed after 3, 12 and 24 months with 
assessment of serum creatinine and abdomi-
nal ultrasound. Cystoscopy was performed 6 
weeks after the induction BCG course, then 
annually with mucosal biopsy of the site of 
the resected primary tumor and randomly 
from the remaining bladder in high-risk pa-
tients. 
Statistical analysis was performed with 
Student’s t-test and Chi-square test and 
























Fig. 3:  Survival according to the number of tumors























Fig. 4:  Survival according to tumor stage.























Fig. 5:  Survival according to tumor grade..
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statistical significance was defined as p < 
0.05. Factors affecting tumor recurrence, 
progression and survival were subjected to 
univariate analysis. Factors that appeared 
significant in univariate analysis were 
subjected to multivariate analysis..
RESULTS                                                            
Pelvic CT scan diagnosed the presence of 
superficial bladder tumors in 98 out of 109 
patients (89.9%), while it overestimated the 
tumor stage in 11 cases. The tumor features 
including multiplicity, stage, grade and asso-
ciation with carcinoma in situ are shown in 
Table 2.
After the induction BCG course 12 pa-
tients (7.5%) were lost to follow-up, 6 (3.8%) 
stopped BCG treatment due to side-effects 
and were further treated with intravesical 
chemotherapy, and 5 (3.1%) died during the 
maintenance BCG course due to tumor-unre-
lated causes. 
Table 1: Presenting symptoms*
















*Some patients had more than one presenting symptom
Table 2: Tumor characteristics
No. %
No. of tumors 1 102 63.8%
2 40 25.0%
3 10   6.2%
4 5   3.1%
5 3   1.9%
Tumor stage T1 138 86.3%
T1 + Tis 9   5.6%
Ta 9   5.6%
Ta + Tis 1   0.6%
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Age had no impact on the outcome of 
the used treatment modality in our patients 
(p>0.855). The overall survival rate at 3 years 
follow-up was 90.4% (Fig.1). There were no 
significant differences in overall survival 
between patients aged <50 and >50 years 
(p=0.168) or numbering those with single 
versus multiple tumors (p=0.966) (Figs. 2 
and 3). On the other hand, overall survival 
was significantly determined by tumor stage 
(p=0.022) and tumor grade (p=0.001) (Figs. 
4 and 5). Out of 160 patients, 70.4% were 
considered tumor-free after a mean follow-
up period of 37 ± 4 months, while tumor 
progression was noted in 16%. 
Recurrence- and progression-free rates at 
3 years did not differ significantly between 
patient groups with single versus multiple 
tumors (Table 3).  A significant association 
between tumor stage and tumor recurrence 
was confirmed (p<0.022), but there was no 
statistically significant association between 
tumor stage and overall survival rate (p>0.219) 
or tumor progression (p>0.295) (Table 3). 
Tumor grade had the most important impact 
on tumor recurrence, progression and overall 
survival rates (Table 3). 
BCG failure was experienced in 29.6% 
due to recurrence and in 18% due to progres-
sion after the second BCG induction course. 
Of the patients with tumor recurrence after a 
second TURT and a second BCG induction 
course, 11 underwent radical cystectomy 
due to aggressive tumor behavior with an in-
creased tumor number (4 cases) or grade (7 
patients). The remaining patients received a 
third TURT session followed by intravesi-
cal chemotherapy instillation. Radical cys-
tectomy was done in 13 patients with tumor 
progression, and combined radiotherapy and 
chemotherapy was administered in 4, while 
palliative treatment was chosen for 3 pa-
tients. 
DISCUSSION                                                        
The European Association of Urology 
(EAU) recommends intravesical BCG 
instillation as the first treatment option in 
Table 3: Correlation between age, tumor features and outcome
Recurrence-free rate (%) Progression-free rate (%) Overall survival rate (%)
Factors Number of cases 3 years p-value* 3 years p-value* 3 years P-value*
Overall 160 70.4 82.0 90.4
Age
     ≤50 yrs 58 64.0 79.6 89.6
     >50 yrs 102 73.9 0.168 83.6 0.555 90.4 0.855
No. of tumors
     1 102 70.9 83.5 93.3
     2 40 61.3 84.6 86.8
     3-5 18 70.6 0.966 79.7 0.385 81.9 0.178
Tumor stage
     Ta 13 100 91.7 100.0
     T1 147 68.4 0.022 81.1 0.295 89.4 0.219
Tumor grade
     1 and 2 124 79.1 92.6 98.1
     3 36 41.4 <0.001 45.9 <0.001 64.1 <0.001
* A p-value ≤ 0.05 is considered significant.
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high-risk and intermediate-risk patients 
after failure of intravesical chemotherapy1. 
However, BCG intolerance and tumor 
recurrence or progression following adjuvant 
BCG therapy have been reported by various 
authors5-9. At Al-Azhar Urology Department 
the treatment policy for superficial bladder 
TCC consists of TURT followed by long-
term adjuvant intravesical BCG therapy 
after exclusion of cases with single, stage Ta, 
grade-1 (low-risk group) bladder carcinoma. 
In accordance with the EAU guidelines 
check-up cystoscopy is routinely done for all 
patients with high-grade Ta and T1 papillary 
tumors10.
In the present study 3.8% of the patients 
stopped BCG therapy due to side-effects 
and were treated with adjuvant intravesical 
chemotherapy; this incidence is comparable 
to other reports5,11. 
In a randomized study carried out by the 
European Organization for Research and 
Treatment of Cancer (EORTC) 957 patients 
with intermediate or high-risk TCC who had 
received adjuvant BCG were evaluated. The 
tumor-free rate was 65% at 3 years follow-
up12. Comparable results were obtained in 
this study with a 70.4% tumor recurrence-
free rate at a mean follow-up of 3 years. In 
contrast, Lockyer et al. reported a tumor-free 
rate of 51% after TURT and adjuvant BCG 
therapy for one year7; this lower rate may be 
attributed to the short term of the maintenance 
BCG adjuvant therapy.
In the present study, BCG failure was 
experienced in 29.6% of the patients due to 
tumor recurrence and in 18% due to tumor 
progression. Relatively similar results were 
described by Bohle et al. with 38.6% post-
BCG tumor recurrence in a meta-analysis 
of 1421 patients4. Furthermore, Mungan et 
al. reported BCG failure in 0% to 42% in 
a review of several studies  with a minimal 
one-year follow-up13. 
Both tumor recurrence and progression 
depend on the tumor risk category and the 
use of long-term intravesical adjuvant BCG 
therapy. In the present study, long-term BCG 
maintenance therapy was associated with 
29.6% tumor recurrence and 18% tumor 
progression, which is significantly less than 
the 51% recurrence rate found by Lockyer et 
al. after short-term BCG therapy7. In another 
study the recurrence rate ranged between 20% 
and 40% depending on the tumor-risk factors 
and the period of follow-up after long-term 
BCG therapy5.
Tumor multiplicity, stage T1, high grade 
and presence of carcinoma in situ are risk 
factors and enhance the possibility of tumor 
recurrence and progression2,3. Similarly in 
this study, tumor recurrence and progression 
were statistically significant in cases with 
stage T1 and high-grade TCC.
In the present study BCG failure was 
significantly determined by tumor grade, 
with recurrence in 41.4% versus 79.1% 
(p=0.001) and progression in 45.9% versus 
92.6% (p=0.001) of patients with grade-3 
compared to grades 1-2 TCC. Orsola et al. 
reported a 42% recurrence and progression 
rate in cases with deep invasion (stage T1) 
superficial bladder cancer14. Lockyer et al. 
reported tumor recurrence in 24% and 29% 
with grade-3 and stage-T1 bladder TCC, 
respectively7. Moreover, the progression rate 
of 12% to 54% in T1 bladder TCC depends 
on the degree of tumor aggressiveness as 
defined in many studies15-17.
In conclusion, standard TURT followed 
by long-term adjuvant BCG therapy is the 
advocated treatment modality for all cases 
of superficial bladder cancer at the Urology 
Department, Al-Azhar University, except in 
cases with Ta, grade-1 tumors. This treatment 
regimen yields a higher tumor-free rate in 
low-grade than in high-grade tumors. BCG 
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failure was significantly noted in cases with 
stage T1, or grade-3 tumors and in those 
associated with carcinoma in situ. The high 
number of cases lost to follow-up in this study 
indicates the importance of educating patients 
about the necessity for repeat assessment 
to improve long-term survival. Different 
treatment modalities can be used after second 
tumor recurrence or progression according 
to the tumor aggressiveness and the patient’s 
preference.
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